Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition

Oncology Reports

Volumn 36, Issue 1, 2016, Pages 271-278

  Zhang, Xiang ^a   Lin, Dan ^a   Jiang, Rong ^a   Li, Hongzhong ^a   Wan, Jingyuan ^a   Li, Hongyuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Epithelial mesenchymal transition; Ferulic acid; Metastasis

Indexed keywords

FERULIC ACID; ANTINEOPLASTIC AGENT; COUMARIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; NEOPLASM METASTASIS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COUMARIC ACIDS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971407843     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4804     Document Type: Article

References (42)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
3. Vanneman M and Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12: 237-251, 2012.
4. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, Conte M, Fini M, Giavaresi G, Berti P, et al: Metastatic breast cancer: An updating. Biomed Pharmacother 60: 548-556, 2006.
5. Rubens RD: 7. Management of advanced breast cancer. Int J Clin Pract 55: 676-679, 2001.
6. Yardley DA: Visceral disease in patients with metastatic breast cancer: Efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 10: 64-73, 2010.
7. Cao H, Xu E, Liu H, Wan L and Lai M: Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract 211: 557-569, 2015.
8. Nieto MA: The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 347-376, 2011.
9. Scheel C and Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 22: 396-403, 2012.
10. Shook D and Keller R: Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120: 1351-1383, 2003.
11. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
12. Thiery JP and Lim CT: Tumor dissemination: An EMT affair. Cancer Cell 23: 272-273, 2013.
13. Bill R and Christofori G: The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett 589: 1577-1587, 2015.
14. Dalerba P, Cho RW and Clarke MF: Cancer stem cells: Models and concepts. Annu Rev Med 58: 267-284, 2007.
15. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ and Garcia-Blanco MA: Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9: 997-1007, 2011.
16. Wu Y, Sarkissyan M and Vadgama JV: Epithelial-mesenchymal transition and breast cancer. J Clin Med 5: pii: E13, 2016. doi: 10.3390/jcm5020013.
17. Sgarbossa A, Giacomazza D and di Carlo M: Ferulic Acid: A hope for Alzheimer's disease therapy from plants. Nutrients 7: 5764-5782, 2015.
18. Kanski J, Aksenova M, Stoyanova A and Butterfield DA: Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: Structure-activity studies. J Nutr Biochem 13: 273-281, 2002.
19. Mancuso C and Santangelo R: Ferulic acid: Pharmacological and toxicological aspects. Food Chem Toxicol 65: 185-195, 2014.
20. Janicke B, Hegardt C, Krogh M, Onning G, Akesson B, Cirenajwis HM and Oredsson SM: The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer 63: 611-622, 2011.
21. Alam MA, Sernia C and Brown L: Ferulic acid improves cardiovascular and kidney structure and function in hypertensive rats. J Cardiovasc Pharmacol 61: 240-249, 2013.
22. Roy S, Metya SK, Sannigrahi S, Rahaman N and Ahmed F: Treatment with ferulic acid to rats with streptozotocin-induced diabetes: Effects on oxidative stress, pro-inflammatory cytokines, and apoptosis in the pancreatic β cell. Endocrine 44: 369-379, 2013.
23. Lin FH, Lin JY, Gupta RD, Tournas JA, Burch JA, Selim MA, Monteiro-Riviere NA, Grichnik JM, Zielinski J and Pinnell SR: Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin. J Invest Dermatol 125: 826-832, 2005.
24. Jayaprakasam B, Vanisree M, Zhang Y, Dewitt DL and Nair MG: Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. J Agric Food Chem 54: 5375-5381, 2006.
25. Cole L, Anderson M, Antin PB and Limesand SW: One process for pancreatic beta-cell coalescence into islets involves an epithelial-mesenchymal transition. J Endocrinol 203: 19-31, 2009.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
27. Gomes LR, Terra LF, Sogayar MC and Labriola L: Epithelial-mesenchymal transition: Implications in cancer progression and metastasis. Curr Pharm Biotechnol 12: 1881-1890, 2011.
28. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
29. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M and Cano A: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. J Cell Sci 116: 499-511, 2003.
30. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24: 2375-2385, 2005.
31. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, et al: Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12: 982-992, 2010.
32. Ikenouchi J, Matsuda M, Furuse M and Tsukita S: Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci 116: 1959-1967, 2003.
33. Martínez-Estrada OM, Cullerés A, Soriano FX, Peinado H, Bolós V, Martínez FO, Reina M, Cano A, Fabre M and Vilaró S: The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J 394: 449-457, 2006.
34. Barone E, Calabrese V and Mancuso C: Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 10: 97-108, 2009.
35. Adluri RS, Nagarajan D, Periyaswamy V and Venugopal PM: Dose-response effect of ferulic acid against nicotine-induced tissue damage and altered lipid levels in experimental rats: A pathohistological evaluation. Fundam Clin Pharmacol 22: 557-567, 2008.
36. Sudheer AR, Muthukumaran S, Kalpana C, Srinivasan M and Menon VP: Protective effect of ferulic acid on nicotine-induced DNA damage and cellular changes in cultured rat peripheral blood lymphocytes: A comparison with N-acetylcysteine. Toxicol In Vitro 21: 576-585, 2007.
37. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
38. Thompson EW, Torri J, Sabol M, Sommers CL, Byers S, Valverius EM, Martin GR, Lippman ME, Stampfer MR and Dickson RB: Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 12: 181-194, 1994.
39. Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W and Kirchner T: Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194: 701-704, 1998.
40. Xue C, Plieth D, Venkov C, Xu C and Neilson EG: The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63: 3386-3394, 2003.
41. Dave B, Mittal V, Tan N Toxicol In Vitro M and Chang JC: Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14: 202, 2012.
42. Foroni C, Broggini M, Generali D and Damia G: Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 38: 689-697, 2012.